This profile describes access and programme structure. Inclusion is not an endorsement, regulatory finding, or clinical recommendation. Prescription decisions belong to a qualified prescriber.
At a glance
Pricing, medicine, location, care, fulfilment, funding, and policy claims are separated below.
An open check means the public sources were not specific enough—not that the service failed the check.
How the program is structured
UK online pharmacy with a clinician-reviewed weight-management service, subscription and one-off routes, and home delivery.
GLP.directory checked the cited public sources on Sep 13, 2026. We reviewed published access, cost, care, fulfilment, funding, cancellation, monitoring, and switching details; we have not audited individual clinical encounters, prescriptions, pharmacy operations, or outcomes.
Availability can change by nation, postcode, prescriber, medical history, licensed indication, product, pharmacy, inventory, and NHS or private route. Inclusion is not an endorsement or regulatory approval. Confirm the patient-specific answer and the pharmacy’s GPhC or PSNI registration before paying or changing care.
Service configuration
These structured fields power the directory filters. They describe the reviewed public route and should be reconfirmed for the selected plan.
- Provider type
- Online pharmacy
- Medicine context
- Semaglutide (Wegovy; Ozempic/Rybelsus for type 2 diabetes) · Tirzepatide (Mounjaro) · Liraglutide (Saxenda / Nevolat where offered) · Orforglipron (Foundayo oral)
- Formats reviewed
- Injection · Oral medicine
- Funding routes
- Private pay
- Service features
- Home delivery · Clinician support · Subscription option · Switching pathway · Simplified logistics
- Access check
- Confirm nation and postcode
- Evidence status
- Regulatory record check flagged
- Research depth
- 4 cited sources · 4 medicine rows · 4 open checks
Recurring cost breakdown
- Published offers from £69; product and terms vary
- The lowest reviewed figure was tied to a specific product or subscription. Compare the ordinary dose-specific total and renewal.
- Introductory codes, dose changes, subscriptions, consultation fees, and delivery can change the effective monthly total.
- Medicine + dose
- Membership or consultation
- Delivery + supplies
- Labs + follow-up
- Renewal after offers
Medication and formulation matrix
| Medication | Form | Regulatory / program path | Published price view |
|---|---|---|---|
| Semaglutide (Wegovy) | Weekly injection | UK prescription-only medicine; indication-specific | Dose and offer dependent; confirm live total |
| Tirzepatide (Mounjaro) | Weekly injection | UK prescription-only medicine; indication-specific | Dose and offer dependent; confirm live total |
| Liraglutide (Saxenda / Nevolat, where offered) | Injection | UK prescription-only medicine; brand and indication specific | Confirm current availability and total |
| Orforglipron (Foundayo) | Daily oral tablet | UK prescription-only medicine; verify current product information | Confirm current dose and total |
Important: UK GLP-1 medicines are prescription only, and each brand has specific licensed uses. A consultation must precede any private prescription. Check a Great Britain pharmacy on the GPhC register or a Northern Ireland pharmacy on the PSNI register.
Nation and postcode availability
- The provider presents a UK service, but a durable public postcode-by-product table was not located.
- Confirm England, Scotland, Wales, or Northern Ireland access, prescriber availability, pharmacy delivery, and the selected medicine during intake.
Clinician access and follow-up cadence
- An online assessment and prescriber decision are required; a questionnaire alone does not guarantee a prescription.
- Follow-up format and response times vary by plan and should be confirmed before purchase.
Pharmacy and fulfillment
- Fulfilment is available only after a valid prescription and stock confirmation.
- Confirm the legal pharmacy name, regulator registration, cold-chain or storage instructions, dispatch cadence, and missed-delivery policy.
Private, NHS and supported funding routes
- The reviewed consumer route is private pay and does not establish NHS eligibility.
- Private purchase does not bypass clinical assessment or guarantee treatment.
Cancellation, refund, and commitment
- Cancellation, refund, and medicine-order cut-offs were not sufficiently standardised across every current plan.
- Read the live checkout and subscription terms before paying, especially once a prescription has been sent to a pharmacy.
Labs, monitoring, and dose management
- No universal included lab panel or monitoring schedule was confirmed across every plan.
- The prescriber may request records, measurements, tests, or two-way consultation based on clinical need and current professional guidance.
Maintenance and switching
- Prior treatment does not guarantee that the new prescriber will continue the same medicine or dose.
- Confirm maintenance criteria, evidence required, refill timing, and support after stopping treatment.
Program snapshot
Online pharmacy and prescribing service
Profiled support: Ongoing clinician access, Simplified intake and fulfillment.
Private pay
The reviewed route is private pay. NHS access uses separate local eligibility and referral pathways.
Verify before purchase
A prescription requires clinical assessment. Confirm the dispensing pharmacy and check its GPhC registration (or PSNI registration in Northern Ireland).
What the advertised program may include
- Online clinical assessment
- Prescription review when clinically appropriate
- UK pharmacy fulfilment where prescribed
- Support described in the selected plan
Useful comparison signals
Based on the provider’s published program structure, this profile is tagged for the following searches. These are filters, not endorsements or clinical recommendations.
- Starting care and comparing first-provider requirements
- Switching providers or continuing an established treatment
- Comparing lower-cost access routes and recurring totals
- Ongoing clinician access
- Simplified intake and fulfillment
Open evidence gaps
These are material details we could not confirm precisely enough from the cited public pages. They are the highest-priority questions to resolve directly.
- Exact postcode and nation coverage by medicine
- Ordinary recurring total at each dose
- Named dispensing pharmacy for the patient route
- Plan-specific follow-up and cancellation terms
Questions to ask before paying
- What is the ordinary monthly total at my dose after any introductory offer?
- Does that include the consultation, medicine, needles or sharps bin, delivery, support, and any subscription?
- Which registered pharmacy will dispense, and does it deliver to my postcode?
- What independent checks and follow-up will the prescriber require?
- If I am switching, what records and timing are needed before my next dose?
Source ledger
Every entry below is a provider-controlled or official public source. A source link documents what was published; it does not independently validate performance, regulatory compliance, safety, or outcomes.
Public medicines, service structure, price framing, and access claims
Provider identity, care model, support, delivery, and contact disclosures
UK licensing, prescription, regulated-pharmacy, counterfeit, and switching safeguards
Official regulatory record, pharmacy response, and follow-up review context